Repare Therapeutics is a technology company.
We are advancing a novel class of targeted therapies that directly address the genetic alterations associated with selected tumors.
Repare Therapeutics has raised $151.0M across 2 funding rounds.
Repare Therapeutics has raised $151.0M in total across 2 funding rounds.
Repare Therapeutics has raised $151.0M in total across 2 funding rounds.
Repare Therapeutics's investors include Amplitude VC, Mott Family Capital, OrbiMed, BDC Venture Capital.
Repare Therapeutics is a clinical-stage precision oncology company developing novel cancer therapies using a proprietary synthetic lethality approach.[1][2][3] It leverages its genome-wide, CRISPR-enabled SNIPRx® platform to identify and target genomic instabilities, such as DNA damage repair, in tumors with high unmet needs, with a pipeline including lunresertib (PKMYT1 inhibitor), RP-3467 (Polo ATPase inhibitor), and RP-1664 (PLK4 inhibitor).[2][3][5] The company serves cancer patients by addressing limitations in existing treatments through highly selective small molecule inhibitors, demonstrating growth via its 2020 NASDAQ IPO (ticker: RPTX) and ongoing Phase 1 trials.[2][5]
Founded in 2016 in Quebec, Canada, by field-leading academics, Repare Therapeutics emerged to systematically apply synthetic lethality insights and advanced platforms for precision oncology drug development.[1][3] The idea stemmed from recognizing untapped potential in targeting synthetic lethal vulnerabilities in cancer cells, particularly those with genomic instability.[3] Early traction built on the SNIPRx® platform, leading to a robust pipeline and public listing on NASDAQ in June 2020 under CEO Steve Forte, with headquarters in St-Laurent and around 129 employees.[1][2]
Repare rides the wave of precision oncology, fueled by advances in CRISPR and genomic profiling that enable synthetic lethality—a strategy exploiting cancer cells' specific genetic weaknesses without harming healthy cells.[1][3][5] Timing aligns with rising demand for targeted therapies amid failures of broad chemotherapy, supported by market forces like increasing cancer incidence, biomarker-driven approvals, and biotech funding for platform technologies.[2][4] It influences the ecosystem by validating SNIPRx® for pipeline building, inspiring similar platforms, and contributing to a shift toward genomic instability-focused treatments in oncology R&D.[3][5]
Repare's next milestones include advancing Phase 1 trials for lunresertib, RP-3467, and RP-1664 toward later-stage data, potentially yielding proof-of-concept in synthetic lethality oncology.[2][5] Trends like AI-enhanced target discovery and combination therapies with immunotherapies will shape its path, amplifying SNIPRx®'s value amid growing precision medicine adoption.[3] Its influence may evolve through partnerships, acquisitions, or expanded indications, solidifying its role as a precision oncology pioneer—building directly on its synthetic lethality foundation to transform cancer care.[1][3]
Repare Therapeutics has raised $151.0M across 2 funding rounds. Most recently, it raised $83.0M Series B in September 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2019 | $83.0M Series B | Amplitude VC, Mott Family Capital, OrbiMed | |
| Jun 1, 2017 | $68.0M Series A | BDC Venture Capital |